Drug · CHEMBL714
ALBUTEROL
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. ALBUTEROL. Drugs and targets, record CHEMBL714. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL714
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
Aerolin, Aerolin 400, Aerolin auto, Airomir, Airsalb, Asmasal clickhaler, Asmasal spacehaler, Asmaven, Asmavent, Cobutolin, Combivent, Combivent udvs, Ipramol steri-neb, Kentamol, Libetist, Maxivent, Proventil, Proventil hfa, Rimasal, Salamol e-breathe, Salapin, Salbulin novolizer, Salbuvent, Salipraneb, Steri-neb salamol, Ventmax sr, Ventodisks, Ventolin, Ventolin cr, Ventolin e-breathe
- ChEMBL
- Other names
- Duoneb, Etinoline, NSC-757417, SCH 13949W, SCH-13949W, Salbutamol, Salbutamolum, Ventoline
- ChEMBL
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| ADRB2 | Beta-2 adrenergic receptor | Beta-2 adrenergic receptor agonist | AGONIST | https://conductscience.org/library/genes/154 |
Source ChEMBL
Diseases46
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 46Source Open Targets
See all 46 diseasesTrials290
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 5 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00400153 | Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | 1,480 | 2009-06-01 | salbutamol | Its name | ClinicalTrials.gov |
| NCT02031640 | A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma | Phase 3 | 1,113 | 2018-01-05 | albuterol | Its name | ClinicalTrials.gov |
| NCT03847896 | A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma | Phase 3 | 1,001 | 2022-09-30 | albuterol | Its name | ClinicalTrials.gov |
| NCT03084718 | An 8-week Dose Ranging Study of CHF 718 pMDI in Asthmatic Subjects | Phase 2 | 610 | 2021-12-14 | albuterol | Its name | ClinicalTrials.gov |
| NCT00310401 | The Effect of Nebulized Albuterol on Donor Oxygenation | Phase 2 | 506 | 2013-09-02 | albuterol | Its name | ClinicalTrials.gov |
| NCT01019694 | Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease | Phase 3 | 470 | 2012-05-01 | albuterol | Its name | ClinicalTrials.gov |
| NCT03380429 | A Clinical Study to Evaluate the Effect of the Connected Inhaler System (CIS) on Adherence to Maintenance Therapy in Poorly Controlled Asthmatic Subjects | Phase 4 | 437 | 2020-02-05 | salbutamol | Its name | ClinicalTrials.gov |
| NCT03137303 | Reducing Diagnostic Error to Improve Patient Safety in COPD and Asthma (REDEFINE Study) | Phase 3 | 402 | 2021-07-22 | albuterol | Its name | ClinicalTrials.gov |
| NCT01698320 | Safety Study of Albuterol Spiromax® in Subjects With Asthma | Phase 3 | 364 | 2015-08-19 | albuterol | Its name | ClinicalTrials.gov |
| NCT03890666 | A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma | Phase 4 | 333 | 2022-10-27 | albuterol | Its name | ClinicalTrials.gov |
1 to 10 of 290
See all 290 trialsComparisons in its trials85
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Albuterol vs Saline: Number of Donor Lungs Used for Transplantation | 74 of 260 | 78 of 246 | 506 | NCT00310401 | Trial comparisons |
| Albuterol vs Saline: serious adverse events | 0 of 260 | 0 of 246 | 506 | NCT00310401 | Trial comparisons |
| Patient-Subject Intervention vs Patient Subject Usual Care: deaths from any cause | 0 of 171 | 1 of 231 | 402 | NCT03137303 | Trial comparisons |
| Patient-Subject Intervention vs Patient Subject Usual Care: serious adverse events | 0 of 171 | 0 of 231 | 402 | NCT03137303 | Trial comparisons |
| Albuterol Spiromax vs Placebo Spiromax: serious adverse events | 1 of 166 | 1 of 165 | 331 | NCT01218009 | Trial comparisons |
| Concurrent Control (CC) vs Digital System (DS): deaths from any cause | 0 of 166 | 0 of 150 | 316 | NCT03890666 | Trial comparisons |
| Concurrent Control (CC) vs Digital System (DS): serious adverse events | 1 of 166 | 1 of 150 | 316 | NCT03890666 | Trial comparisons |
| Fluticasone Propionate vs Prednisone: deaths from any cause | 0 of 123 | 0 of 128 | 251 | NCT01687296 | Trial comparisons |
| Fluticasone Propionate vs Prednisone: serious adverse events | 1 of 123 | 2 of 128 | 251 | NCT01687296 | Trial comparisons |
| Treatment A (PT027) [Experimental] vs Treatment B (PT007) [Active Comparator]: deaths from any cause | 0 of 100 | 0 of 101 | 201 | NCT05555290 | Trial comparisons |
1 to 10 of 85
See all 85 comparisons in its trialsPapers from its trials139
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL714
GET https://conductscience.org/api/drugs/v1/CHEMBL714/diseases?page=2